OBJECTIVES: Mastitis is one of the most frequent and costly diseases in the dairy industry with gram-negative bacteria being the main causal agent. Since most antibiotics have minimal effect on shortening the duration of clinical mastitis caused by gram-negative pathogens (gram-CM) and because of a high spontaneous cure rate, antibiotics are often not recommended for treating Gram-CM. The purpose of this study was to develop a model comparing 5-day treatment with ceftiofur hydrochloride to no treatment of gram-CM, also allowing easy adaptations to reflect the high variability of prices and cost data in livestock. METHODS: A decision tree was developed in MS Excel considering first and recurrent CM episodes, culling and death of cows with gram-CM. Cure rates and other clinical data were derived from published studies. Costs and losses associated with CM and its treatment, culled or dead cows as well as income generated from saleable milk production or sold cows were considered. Cost and income values were derived from public sources (US-2010, perspective of the producer). All input parameters were varied extensively in one-way sensitivity analyses. RESULTS: With US-2010 cost/ prices, income from saleable milk was $3,039.35 (ceftiofur) and $3069.67 (no treatment), and costs associated with the disease and treatment totaled to $215.12 (ceftiofur) and $246.60 (no treatment) over the entire lactation period, resulting in a $1.16 higher margin per treated cow with a 5-day treatment with ceftiofur compared to no treatment of gram-CM. More cows were cured and fewer cows culled or died with ceftiofur. The model was most sensitive to ceftiofur cure rate and selfcure rate. CONCLUSIONS: Compared to no treatment, ceftiofur's higher treatment costs and less income due to milk discard were offset by a better efficacy, resulting in less disease associated costs of gram-CM.
OBJECTIVES: Data documenting the incremental economic and health burden of HCV infections will be required to evaluate the comparative effectiveness of new, emerging HCV therapies. Our objective is to estimate the incremental cost associated with hepatitis C infections [HCV] in real-world clinical practice. METHODS: Six years of de-identified data from a U.S. health insurer [2003] [2004] [2005] [2006] [2007] [2008] were used to identify patients with HCV with at least two years of data prior to and following their first HCV diagnosis or the start of antiviral drug therapy [index date]. Non-HCV patients with 2 years of eligibility were identified and patients with a preindex diagnosis for HIV, hepatitis B, cirrhosis, liver cancer or a liver transplantation were excluded. Propensity score matching was used to match the patients with HCV to similar non-HCV patients on a 1-to-1 ratio. The incremental impact of HCV on post-index cost and adverse event risk were estimated controlling for patient demographics, diagnostic profile, and prescription drug profile. RESULTS: The 8,861 HCV patients and 8,861 matched non-HCV patients in the study sample were 60% male, age 50 years old. Post-index total cost of HCV and non-HCV patients were $37,390 and $13,575, respectively, in the first year. The incremental cost of HCV was estimated at ϩ$23,406 due primarily to higher costs for ambulatory care [ϩ$6,531] . CONCLUSIONS: Newly diagnosed HCV patients experience significantly higher cost and adverse event risk relative to matched non-HCV patients. These results highlight the need for safe, tolerable and effective antiviral therapies, and the need for risk predicting tools to identify HCV patients at high risk for adverse events.
PIN14 ECONOMIC BURDEN OF SEVERE SEPSIS IN A VERTICALLY INTEGRATED HEALTH CARE SYSTEM (IHS)
Choe Y 1 , Lamerato L 2 , Zervos M 2 , Stern L 3 , Hendlish S 3 , Ogbonnaya A 3 , Fain R 1 1 Eisai, Inc., Woodcliff Lake, NJ, USA, 2 Henry Ford Health System, Detroit, MI, USA, 3 Analytica International Inc., New York, NY, USA OBJECTIVES: Severe sepsis (SS) contributes to a high economic burden among critically ill patients. The objective of the study was to describe SS population and determine associated costs. METHODS: Data was drawn from a large IHS (Jan 2002 to Dec 2008) and included two groups of adult patients; SSD: SS or septic shock ICD-9 code (995.92 and 785.52); and NSSD: SS criteria by Angus (2001) and Martin (2003) . Patients were evaluated at index hospitalization, 30-days (30D), 30-days-6months (30D-6M), and 6-months-1year (6M-1YR) post-discharge. Comorbidities, antibiotic use, supportive treatment, mortality, and costs were analyzed. Costs were adjusted to 2009 US Dollars using the overall urban CPI; 0.65 (cost-to-chargeratio) was applied to charge data. Follow-up cost analysis was limited to patients with complete data at the beginning of each evaluation period. RESULTS: The cohort included 17,256 patients: 3,229 (19%) SSD and 14,027 (81%) NSSD. The groups had similar baseline demographics and comorbidities. SSD had a higher rate of ICU admission (81% vs. 47%). Nearly all received antibiotics. Supportive treatments included vasopressors (66% vs. 19%) and mechanical ventilation (71% vs. 39%).
Mean length of stay (LOS) was 21Ϯ2d for SSD and 14Ϯ14d for NSSD. Hospital mortality was 40% for SSD and 11% for NSSD; overall mortality at 1-year pdschg was 61% and 39%, respectively. Mean cost of hospitalization was $75KϮ107K, with SSD costing almost double NSSD ($123KϮ149K vs. $64KϮ$91K). In all three follow-up periods, NSSD incurred higher costs ($18KϮ34K vs. $14KϮ27K for 30D, $54KϮ102K vs. $42KϮ81K for 30D-6M, and $34KϮ67K vs. $27KϮ56K for 6M-1YR. CONCLUSIONS: SSD patients have higher rates of mortality, both during hospitalization and in the year following, compared to NSSD patients. The higher mean hospitalization costs for SSD may be due to longer LOS/ more intensive resource use. The lower overall 1-year mortality rate in NSSD may be associated with higher follow-up costs.
PIN15 ECONOMIC BURDEN OF SURGICAL SITE INFECTIONS IN HIP AND KNEE ARTHROPLASTY -A COST-OF-ILLNESS-STUDY FOR GERMANY
Hanstein TJB 1 , Gaiser G 2 1 University of Applied Sciences Ludwigshafen, Ludwigshafen am Rhein, Rheinland-Pfalz, Germany, 2 Heraeus Medical GmbH, Wehrheim, Germany OBJECTIVES: The treatment of surgical site infections (SSI) is associated with high costs for the statutory health insurance (SHI) and for hospitals. The DRG-reimbursement for septic revisions seems to be not cost-covering for hospitals. Without an Arthroplasty Register for Germany, exact numbers for SSI in hip arthroplasty and knee arthroplasty are not available. Also there is no approximation for the financial impact, yet. The purpose of this work is to estimate the financial impact and possible risk of SSI in knee and hip arthroplasty for SHI and hospitals. METHODS: To estimate the number of SSI for Germany, a projection for all SSI in primary hip and knee replacements in Germany (Nϭ372.851) was made with data from the KISS module surgical ("Krankenhaus-Infektions-Surveillance-System"). Two approaches were used to assess the costs: First, treatment expenses from the Barmer GEK-report were used and second a bottom-up analysis based on the medical and pharmaceutical costs of the treatment algorithm for SSI. RESULTS: The revision treatment of SSI resulted in a financial burden of at least € 22.407.350 for hip replacement and € 13.760.280 for knee replacement for the SHI. Due to the even higher medical and pharmaceutical costs for the treatment of SSI in hospitals, SSI can cause a financial loss to them. CONCLUSIONS: To achieve a cost-covering treatment of SSI in hospitals, the several methods of reducing the risk of SSI should be checked with a cost-minimization-analysis. Then, hospitals have the opportunity to calculate the risk of higher SSI-rates against higher costs for primary replacement with a reduced risk of SSI. For the SHI a cost-benefit-analysis could be helpful to make a decision about requirements on methods used in primary replacement in hospitals to reduce the rate off SSI. A German Arthroplasty Register should include the collection of SSI data in its dataset.
